| name | endo-vitd-supplementation-prediabetes |
| description | Suggests empiric vitamin D supplementation plus lifestyle modification to reduce diabetes progression in adults with high-risk prediabetes. Triggered by clinician questions such as "Should I prescribe vitamin D to this patient with prediabetes?" or "Is vitamin D supplementation indicated for prediabetes management?" |
Vitamin D supplementation for prediabetes
STEP 1 — Gather Information
Collect fasting plasma glucose, HbA1c, and 2‑hour glucose after a 75‑g oral glucose tolerance test to confirm prediabetes (meeting 2 or 3 ADA glycemic criteria). Screen for conditions that constitute established indications for vitamin D testing/treatment (e.g., hypocalcemia, hyperparathyroidism, granulomatous diseases) and assess whether lifestyle modification (diet, physical activity, weight loss) is already in place.
STEP 2 — Rule In / Rule Out
Is the patient an adult with high‑risk prediabetes (≥2 abnormal ADA criteria) and without contraindications to empiric vitamin D?
- Yes → proceed to STEP 3.
- No → do not prescribe empiric vitamin D for diabetes prevention; manage prediabetes with lifestyle modification alone and consider standard indications for vitamin D testing if present.
STEP 3 — Classify or Stratify
Classify as a candidate for empiric vitamin D supplementation; the guideline does not require baseline 25(OH)D testing or stratification by dose, age, or BMI for the recommendation (though greater benefit may be seen in those >62 y, baseline 25(OH)D <12 ng/mL, or BMI <30 kg/m²).
Decision: proceed to prescribe empiric vitamin D supplementation.
STEP 4 — Decide
Prescribe empiric vitamin D supplementation (dose range used in trials: 842–7543 IU daily; weighted average ≈3500 IU/day) in addition to continuing lifestyle modification. Do not obtain routine 25(OH)D levels to guide dosing; re‑evaluate lifestyle adherence and glycemic parameters at routine follow‑up intervals.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on 25(OH)D testing to decide supplementation; avoid high‑dose intermittent bolus regimens without monitoring for hypercalcemia; do not use in patients with granulomatous diseases, certain lymphomas, or primary hyperparathyroidism where vitamin D may increase calcium absorption risk; do not substitute vitamin D for lifestyle modification; avoid exceeding the tolerable upper intake level without clinical supervision (generally ≤4000 IU/day unless monitored).
Concrete Clinical Example
A 58‑year‑old man with BMI 31 kg/m² has fasting glucose 112 mg/dL, HbA1c 6.1 %, and 2‑hour glucose 158 mg/dL (meets 2 ADA criteria). He has no history of hypercalcemia or granulomatous disease and has begun a reduced‑calorie diet and walking 150 min/week. According to the guideline, prescribe empiric vitamin D supplementation (e.g., 2000–4000 IU daily) alongside continued lifestyle modification; do not order a 25(OH)D level to guide the decision.
Source: Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2024, https://doi.org/10.1210/clinem/dgae290
